ngr peptide

Cell-penetrating peptide

Aminopeptidase N Ligand (CD13) NGR peptide, a polypeptide that targets CD13, functions as a carrier for mediating intracellular transmission and is commonly utilized in cancer research [1][2].

NGR peptide Trifluoroacetate, containing the asparagine-glycine-arginine (NGR) motif, is a synthetic peptide recognized by CD13/aminopeptidase N (APN) receptor isoforms that are selectively overexpressed in tumor neovasculature, and NGR peptide Trifluoroacetate is thus employed in targeted drug delivery and diagnostic strategies designed to exploit tumor-specific vasculature expression patterns, thereby advancing cancer research.

NEP(1-40), N-terminal uncapped, is an analog of NEP(1-40) without acetylation at the N-terminus. NEP(1-40) acts as a peptide antagonist of the Nogo-66 receptor (NgR).

NEP(1-40) TFA is a peptide antagonist of the Nogo-66 receptor (NgR), which attenuates myelin-derived inhibition and mitigates injury-induced shifts in microglial morphology distributions [1].

DSPE-PEG1000-NGR is a PEG compound composed of DSPE and the Asn-Gly-Arg (NGR) peptide. The NGR peptide has the capability to target the CD13 antigen present in tumor vasculature. DSPE-PEG1000-NGR can be utilized for drug delivery.

DSPE-PEG5000-NGR is a PEG compound composed of DSPE and the Asn-Gly-Arg (NGR) peptide. The NGR peptide has the capability to target tumor vasculature antigen CD13. DSPE-PEG5000-NGR is applicable in drug delivery.

DSPE-PEG2000-NGR is a PEG compound composed of DSPE and the Asn-Gly-Arg (NGR) peptide. The NGR peptide specifically targets the tumor vasculature antigen CD13. This compound is suitable for drug delivery applications.

DSPE-PEG3400-NGR is a PEG compound composed of DSPE and the Asn-Gly-Arg (NGR) peptide, which targets tumor vascular antigen CD13. DSPE-PEG3400-NGR can be employed for drug delivery.

Peptide fragment corresponding to residues 1 - 40 of Nogo-66, the domain of the myelin protein Nogo that inhibits axonal outgrowth. Acts as a competitive antagonist at the Nogo-66 receptor (NgR); blocks Nogo-66- and CNS myelin-induced inhibition of axonal